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Summary.-Serum prolactin concentrations were measured by radioimmunoassays
in 98 patients with established carcinoma of breast, 12 patients with cystic mastitis
and 10 patients with gynaecomastia and compared withthat of age matched normal
control women. The serum prolactin levels in the patients with breast cancer,
gynaecomastia or cystic mastitis were observed to be similar to that in normal
women. It was interesting to note that the levels of prolactin in the Iuteal phase
of the cycle were higher than that in the early follicular phase in normal women.
A CONSIDERABLE body of evidence
has accumulated indicating prolactin
dependence in experimental mammary
cancer (Pearson et al., 1969; Boot, 1970;
Yanai and Nagasawa, 1972; Meites et
al., 1972). Several lines of indirect evi-
dence have indicated its role in human
breast cancer. Hypophysectomy may
lead to remission of metastatic breast
cancer in patients whose cancers have
shown no response to both oophorectomy
and adrenalectomy. Hypophysectomy
leads to remission of the disease in some
30% of patients (Atkins et al., 1960).
It has been assumed that this effect is
caused by reduction in mammatropic
action ascribed to several anterior
pituitary hormones. At the same time,
remission of the disease in metastatic
breast cancer was observed in some of
the patients treated with pituitary stalk
section, which generally leads to an in-
crease in prolactin levels (Thurkington,
Underwood and Vanwyk, 1971). Utiliz-
ing the stimulation of pentose shunt
activity as a criterion for hormone de-
pendence, Salih et al. (1972) compared
the hormonal dependence of cultured
tumour slices and found prolactin de-
pendence in 20% of 50 breast cancers
and 12% also showed affinity for oestro-
gen.
With the identification of human
prolactin as a distinct hormone from
human growth hormone and the avail-
ability of specific radioimmunoassay for
the measurement of circulating prolactin
levels, it became possible to explore the
role of this hormone in human mammary
cancer. Earlier reports by Murray, Mo-
zaffarian and Pearson (1972) have shown
that, at least in some of the breast cancer
patients, serum prolactin levels are high,
whereas Forrest (1972) observed normal
levels in breast cancer. Boyns et al.
(1973) have indicated that the level of
prolactin is not significantly higher in
breast cancer patients than in normal
controls. These authors suggested that
further work is essential before coming
to an unequivocal conclusion. Mittra,
Hayward and McNeilly (1974) also did
not find a difference in mean basal plasma
prolactin levels in breast cancer patients
and control women. Shiu et al. (1973a)
were unable to find elevations in serum
lactogenic activity in a group of breast
cancer patients by using a sensitive
radioreceptor assay (Shiu, Kelly and
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well with radioimmunoassay measure-
ments in the same sera (Friesen et al.,
1973). Kwa et al. (1974) found a high
prolactin level only in women with a
family history of the disease. Recently,
Murray and Sarfaty (1974) have reported
higher serum prolactin levels in women
with advanced cancer of breast.
In the present study specific homo-
logous radioimmunoassay was used to
assess circulating prolactin levels in breast
cancer.
MATERIALS ANI) AIETIIODS
Antigen and antiserurn.-Highly purified
human prolactin (HPr V.L.-]) which served
as a reference standard as well as a radio-
iodinated hormone (after iodination) in the
assay system, highly purified LH and anti-
sera developed against each in rabbits,
wvere generously provided by NIAMD, Na-
tional Institute of Health, Bethesda, U.S.A.
11nd IRP HMG, kindly supplied by the
W.H.O., was used as a standard for serum
LH.
Iodination .-Carrier-free 1251 was ob-
tained from the Radiochemical Centre,
Aniersham, England. The method of Green-
wood, Hunter and Glover (1963) as modified
by Midgley (1966) was used to iodinate
HPr. To 2 5 ,tg of HPr dissolved in phos-
phate buffer (plH 7 5), l mCi 1251 and 20 /tg
(10 pi) of choramine-T were added as an
oxidizing agent and allowed to react for
30 s at room temperature. The reaction
was stopped with the addition of 75 jug
(35 tul) of sodium metabisulphite. Separa-
tion of iodinated hormone from unreacted
iodine and damaged hormone was achieved
by fractionating the reaction mixture through
a column of Sephadex G-75, which had been
equilibrated with 50o egg white in phosphate
buffer with 0-14 mol/l saline (PBS). Gener-
ally 3 radioactive peaks were observed. The
radioactive material that was eluted in the
void volume represented damaged and aggre-
gated hormone. The radioactive material
that was eluted from the column at a position
wrhere the native hormone appears was
used for the studies. The specific activities
of labelled hormone ranged from 100 to
150 ,uCi/uig. To find out the extent of
hormone damaged during iodination, 1251
labelled HPr was precipitated by excess
12
of antibody to the same. It was found that
80% of the labelled hormone could be
precipitated by the antibody.
A8say.-All assays were carried out by
the double antibody technique as described
by Midgley (1966). After the incubation of
the antigen with the antiserum and labelled
hormone for 48 h at 4°C in a final volume
of 0-6 ml, a second antibody (sheep anti-
rabbit gamma globulin) was added. Incuba-
tion wvas continued for another 48 h at 4°C.
At the end of the incubation period, the
contents of each tube were diluted to 3 ml
with PBS containing 0-1% gelatin. Finally,
bound and free hormones were separated
by centrifugation. The tubes were drained
and the amount of bound radioactive tracer
was determined by gamma ray spectrometry.
All serum samples wvere run in duplicate at
2 dose levels. The inter-assay coefficient
of variation was 7-8°/, and that of intra-
assay was less than 5%0. The concentration
of prolactin was expressed in terms of ng
of standard human prolactin as supplied by
NIAMD, Bethesda, U.S.A.
Clintical material.-Serum samples separ-
ated from whole blood were stored at -20°C
until used. Serum samples from 98 patients
with established carcinoma of breast, 12
patients with cystic mastitis and 10 patients
wvith gynaecomastia Awere collected from the
clinic at the Tata Memorial Hospital. Non-
hospitalized patients wvere used for the
present study. Histopathological diagnosis
was carried out in the pathology department
of the hospital. Blood samples from 22
normal women in the age group 31-50 years
and 12 in that of 51-60 years were also
collected for comparison. Blood samples
from 18 normal menstruating women in
follicular and luteal phases of the cycle,
12 menopausal and postmenopausal women,
18 pregnant women in the 1st, 2nd and 3rd
trimester of pregnancy, 10 lactating amenor-
rhoeic wonmen, 6 women with galactorrhoea
and 8 normal men were also collected for
comparative studies. Four healthy female
volunteers belonging to the 25-35 age group
with regular menstrual cycles (28-30 days)
were selected for serial estimations of pro-
lactin in the same subject during the
menstrual cycle. Blood samples were col-
lected at intervals of 48 h during the 7th
to 23rd days of the cycle. The day oni which
LH surge was observed was considered
as Day 0. As far as could be ascertained,
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no patient was receiving phenothiazines,
L-DOPA, inhibitors of monoamine oxidase
or other drugs known to affect the secretion
of prolactin. Prolactin is known to have
circadian rhythm (Nokin et al., 1972; Sassin
et al., 1972). The highest levels are observed
during sleep. Hence care was taken to
collect blood samples from all the subjects
in the afternoon between 1 p.m. and 4 p.m.
Wherever possible, repeated samples were
collected after an interval of a few days or
months. Lactational status as well as
pregnancy were ruled out in women with
breast cancer, as well as in women with
other pathological conditions of the breast.
RESULTS
Figure 1 shoNs the standard curve of
HPr in a homologous assay system.
The sensitivity of the assay is up to
12 ng/ml. Figure 2 indicates that the
distribution of serum prolactin levels in
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the patients with breast cancer does not
differ from that of the normal control
group. It is interesting to note that
amongst normal women belonging to
the age group 31-50 years and having
menstrual cycles, the prolactin values
in 3 subjects are higher than 35 ng/ml
serum and vary from 45 to 60 ng/ml
serum. Similarly, in breast cancer pa-
tients, 12 (10 in the age group 31-40 years
and 2 in that of 41-50 years) have pro-
lactin values higher than 30 ng/ml serum,
varying from 39 to 50 ng/ml serum.
Finally, the serum prolactin levels in
patients with cystic mastitis and gynaeco-
mastia are similar to that of normal
women. The Table shows the mean
prolactin values in various physiological
and pathological conditions. It is in-
teresting to note that in normal menstru-
ating women the average serum pro-
lactini concentration, as well as its range
+2
+1
0 -
0
- 1
-2
20
FTc. 1. )Dose response cuirve for human prolactinl.
E
I I I I I I
162CIRCULATING LEVELS OF PROLACTIN IN HUMAN BREAST CANCER
60k
551-
50 -
^% 45
c 40
z
' 35
U
S -J
0 30
0.
2 25
w
Cl) 20
15
10
5
_ . .
_ .
_-
_-
_ '
i i i i i i i i - i
31-50 50-60 31-40 41-50 50-60 30-60
(22) (12) (42) (30) (26) (12)
ICYSTIC
CONTROL BREAST CANCER MASTITIS
30-60
(10)
GYNECOMA-
-STIA
FIG. 2.-Serurn prolactin concentrations in patients with breast cancer, cystic mastitis and
gynaecomastia.
TABLE. Serum Prolactin Levels in Different Physiological Conditions
Groups
Follicular phase
Luteal phase
Menopausal and postmenopausal
ng/ml
Total number , A
studied Mean and s.e. Range of prolactin
10 21±4 5-30
8 43±5 18-60
12 20±3 8-35
Pregnancy 1st Trimester
2nd Trimester
3rd Trimester
Lactation and amenorrhea
Galactorrhea
Breast, cancer
Cystic mastitis
Gynaecomastia
Normal men
Age 31-40
Age 41-50
Age 51-60
MIenstrual cycle
6
6
6
10
6
30±4
111±42
270± 62
47&7
186±57
22± 3
19±2
17±2
14±2
16±2
14±4
42
30
26
12
10
8
15-40
24-300
80-450
26-101
50-400
6-50
12-42
9-24
9-20
12-20
2-41
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in the luteal phase of the cycle, is higher
than in the early follicular phase, the
range and mean value being 18-60 ng/ml
serum and 43 ± 5 ng respectively in the
luteal phase while it varies from 5 to 30 ng
and has a mean value of 21 ± 4 ng/ml
serum in the early follicular phase.
DISCUSSION
Our studies on 98 breast cancer
patients using a homologous radioimmu-
noassay indicate that the range of pro-
lactin concentration in the above group
does not differ from that observed in
the normal control subjects. Our results
confirm those reported by Boyns and
his co-workers who employed heter-
ologous (Boyns et al., 1973) and
homologous (Wilson et al., 1974) radio-
immunoassays. Mittra et al. (1974) also
reported similar observations using homo-
logous assay.
In our studies on control women,i.e.
normal menstruating women, we found
higher levels of prolactin, ranging from
18 to 60 ng, during the progestational
phase (Table). The above assumption is
further supported by the fact that what-
ever high values of prolactin were ob-
tained in breast cancer patients belonged
to the age group 31-50 years, whereas
in the case of menopausal and post-
menopausal patients none of the values
were higher than 30 ng (Fig. 2). A
similar pattern of prolactin was observed
in normally menstruating women in whom
blood samples were collected on every
alternate day of the cycle (Fig. 3).
In contrast, Ehara et al. (1973), Midgley
and Jaffe (1972) and Friesen et al. (1972)
have reported that there is no variation
in circulating prolactin levels throughout
the cycle. However, Vekemans et al.
(1972) observed a significant increase
of prolactin at mid-cycle and during the
luteal phase. Robyn et at. (1973) also
indicated that during the luteal phase
prolactin values are at a significantly
higher mean level than during the fol-
licular phase.
Just on the basis of similar levels of
prolactin in cancer and non-cancer pa-
tients, it would be wrong to arrive at
a conclusion that prolactin has no signi-
ficant role in mammary tumorigenesis.
It is likely that the cases in which the
growth of human breast cancer is shown
to be dependent on prolactin might be
so at a physiological level. Secondly, the
hormone concentration available at a
cellular level would be of a greater
physiological significance. We have
shown, in our earlier studies on experi-
mental mammary cancer in mice, that
mammary glands of a susceptible strain,
namely C3H/Jax, have 6 times higher
binding capacity for radioiodinated
human placental lactogen (HPL) than
that of resistant.,C57 BL strain (Sheth,
RanadiveandShth, 1974). Theseresults
imply the importance of receptor studies.
Hobbs et al. (1973) and Furth (1973) have
stressed the significance of investigations
on the in vitro tests to recognize the
prolactin receptors in the mammary
gland and its tumour. The occurrence
of receptor proteins in certain tissues of
the body suggests two important lines
of investigation. First, the receptor pro-
teins may provide a mechanism by
which target cells trap the hormones
and convey them to the nucleus. If
this hypothesis is correct, it may be
possible to investigate at a molecular
level the action of specific hormones
within cells. Second, the presence or
absence of specific receptors in lesions
of the target tissues could provide evi-
dence concerning the hormonal require-
ment of the lesiotis.
The evidence now suggests that pro-
lactin may be involved in the main-
tenance, if not initiation, of some human
breast cancers. Further critical investi-
gations are required to correlate cir-
culating prolactin levels before and after
therapy, andinvitroprolactindependence,
with the clinical response to medical
or surgical therapy aimed at lowering
prolactin secretion. The fact that some
success was achieved in regression of
breast cancer by treatment with agents
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like CB-154 (drugs derived from ergot
alkaloids, Schulz et al., 1973) and L-DOPA
(Frantz et at., 1973), which inhibit pro-
lactin secretion, implicates the role of
prolactin alone, or acting synergistically
with other hormones, in the aetiology
of breast cancer. Further studies are
warranted.
A recent hypothesis put forward by
Mittra et at. (1974) suggests that raised
levels of prolactin may not have any
pathological effect on mammary epi-
thelium. However, it is possible that an
abnormal hormonal environment could
alter the sensitivity of mammary epi-
thelial cells to the growth promoting
effect of prolactin which might lead to
dysplasia and eventual neoplasia. The
experimental findings in animals support
such a possibility (Mittra, 1974). Ex-
perience collected to date with experi-
mental animals has taught us that the
growth, development and function of
mammary gland tissues depend upon the
interaction of these tissues with many
hormones. The importance of an indi-
vidual hormone has been emphasized
from time to time but the fact remains
that no single hormone is sufficient when
administered at a physiological level.
The deviation from the normal hormonal
requirement found in abnormal tissue
mustbe measuredinterms ofrequirements
for a variety of hormones rather than
requirement for a single hormone.
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